Moderna Stock: Buy, Sell, or Hold in 2022?
Moderna (NASDAQ: MRNA) has posted major gains for two straight years. In 2020, investors bet on the biotech company's ability to bring a coronavirus vaccine to market, and they won. Moderna scored Emergency Use Authorization and finished the year with a 434% share gain. This year, Moderna shares have advanced another 192%. That's after the company reported billions of dollars in revenue and profit every quarter.
Now, as we head toward 2022, you may be wondering if this dynamic biotech company can keep up the momentum. Are we reaching the final chapters of the Moderna investment story? Or is there a lot more to come? In 2022, we can buy, sell, or hold Moderna stock. Let's see which option might offer us the best return down the road.
Image source: Getty Images.
Source Fool.com
